Boron Phenylalanine With or Without Mannitol in Treating Patients With Glioblastoma Multiforme

This study has been terminated.
(Sponsor Decision)
Sponsor:
Information provided by (Responsible Party):
Cancer Research UK
ClinicalTrials.gov Identifier:
NCT01233492
First received: November 2, 2010
Last updated: October 7, 2013
Last verified: October 2013
  Purpose

RATIONALE: Giving boron phenylalanine in different ways and measuring it in tissue in patients with glioblastoma multiforme may help in planning better radiation therapy, such as boron neutron capture therapy, for patients in the future.

PURPOSE: This phase I trial is studying the side effects, best dose boron phenylalanine, and best way of giving it with or without mannitol in treating patients with glioblastoma multiforme.


Condition Intervention Phase
Brain and Central Nervous System Tumors
Drug: boron phenylalanine
Drug: mannitol
Other: biologic sample preservation procedure
Radiation: radiation therapy treatment planning/simulation
Phase 1

Study Type: Interventional
Study Design: Masking: Open Label
Primary Purpose: Treatment
Official Title: A Cancer Research UK Pharmacokinetic Study of BPA in Patients With High Grade Glioma to Optimize Uptake Parameters for Clinical Trials of BNCT

Resource links provided by NLM:


Further study details as provided by Cancer Research UK:

Primary Outcome Measures:
  • Optimal dose of boron phenylalanine (BPA) [ Designated as safety issue: No ]
  • Causality of each adverse event to BPA and grading severity according to NCI CTCAE Version 3.0 [ Designated as safety issue: Yes ]
  • Pharmacokinetic (PK) parameters used to construct a PK model with the aim of being able to predict boron up-take by tumor and normal brain tissue [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Change in mean dose to the planning target volume of greater than 15%, for a constant maximum and mean dose to normal tissue in any treatment cohort of the study [ Designated as safety issue: No ]
  • Change in the intra-nuclear percentage of 10B atoms in any cohort of the study of greater than 20% [ Designated as safety issue: No ]
  • Establishment of a repository of samples including serum and tumor tissue for future studies using techniques such as proteomics and DNA array [ Designated as safety issue: No ]

Estimated Enrollment: 36
Study Start Date: October 2007
Study Completion Date: September 2013
Primary Completion Date: September 2013 (Final data collection date for primary outcome measure)
Detailed Description:

OBJECTIVES:

Primary

  • To determine the optimal way to deliver boron phenylalanine (BPA) with or without mannitol in terms of route (intravenous vs intraarterial), blood-brain barrier disruption, and dose for use in subsequent therapeutic trials of boron neutron capture therapy (BNCT) in patients with high-grade glioma.
  • To evaluate the toxicity profile of BPA administered intravenously or intra-arterially.
  • To evaluate the pharmacokinetic behavior of BPA using samples of blood, urine, tumor tissue, normal brain tissue, extracellular fluid, and cerebrospinal fluid.

Secondary

  • To produce indicative treatment plans using BPA administered either intravenously or intra-arterially with or without mannitol to support the design of combination studies using BPA and thermal neutrons for BNCT.

Tertiary

  • To evaluate the micro-distribution of boron resulting from the different routes of administration using secondary ion mass spectroscopy (SIMS).
  • To store surplus tissues removed during the trial for possible future studies.

OUTLINE: This is a dose-escalation study.

  • Stage 1 (Route and Blood Brain Barrier Disruption [BBBD]): Patients receive one dose of boron phenylalanine intravenously (IV) or intra-arterially (IA) over 2 hours. Some patients may receive mannitol IA over 30 seconds before receiving boron phenylalanine. Patients then undergo planned biopsy of the tumor. Some patients may then undergo immediate surgical debulking of the tumor.

Boron distribution data is analyzed to determine the optimal administration schedule. Patients in stage 2 receives boron phenylalanine via the optimal route established in stage 1. If addition of mannitol is found to be beneficial, then mannitol is used in stage 2

  • Stage 2 (Dose-escalation): Patients receive 1 or 2 doses of boron phenylalanine IV or IA (as determined in stage 1) over 2 hours on day 1. Patients may also receive mannitol IA as in stage 1.

Tumor tissue, normal brain tissue, and cerebrospinal fluid are collected during biopsy and/or surgery. Some patients undergo blood, urine, extracellular fluid sample collection periodically for pharmacokinetic studies. Tumor tissue will be stored for future studies.

After completion of study treatment, patients are followed for 7 days and then once a month.

Peer Reviewed and Funded or Endorsed by Cancer Research UK

  Eligibility

Ages Eligible for Study:   45 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

DISEASE CHARACTERISTICS:

  • Radiologically and clinically suspected solitary glioblastoma multiforme

    • High-grade disease
  • Agreed to undergo stereotactic biopsy as part of routine diagnostic work-up

PATIENT CHARACTERISTICS:

  • WHO performance status 0-2 (0-1 for patients ≥ 65 years old)
  • Life expectancy > 4 months
  • Hemoglobin ≥ 9.0 g/dL
  • Neutrophil count ≥ 1.5 x 10^9/L
  • Platelet count ≥ 100 x 10^9/L
  • Serum bilirubin ≤ 1.5 times upper normal of limit (ULN)
  • AST ≤ 1.5 times ULN
  • Uncorrected EDTA-Isotope creatinine clearance ≥ 40 mL/min
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use two forms of effective contraception 4 weeks prior to, during, and for 6 months after completion of study therapy
  • Able to cooperate with procedures and follow-up
  • Not at high risk of complications from blood-brain barrier disruption with mannitol on pre-treatment CT scan (an open quadrigeminal plate cistern, absence of dilatation of the contralateral frontal horn, and absence of uncal herniation)
  • No history of uncontrolled seizures
  • No phenylketonuria
  • No current or previous malignancies at sites other than the brain, except for adequately treated cone-biopsied carcinoma in-situ of the uterine cervix or basal cell or squamous cell carcinoma of the skin
  • Not at high medical risk due to nonmalignant systemic disease, including active uncontrolled infection
  • No known hepatitis B, hepatitis C, or HIV positivity by serology
  • No concurrent congestive heart failure, history of NYHA class III-IV cardiac disease, history of myocardial infarction or active ischemic heart disease within the past year, or history of cardiac arrhythmia or thromboembolic disease
  • No other condition that, in the investigator's opinion, would not make the patient a good candidate for the clinical trial

PRIOR CONCURRENT THERAPY:

  • At least 12 hours since prior and no concurrent steroids
  • At least 48 hours since prior phenylalanine-containing drinks (e.g., colas)
  • At least 48 hours since prior excessive consumption of phenylalanine-containing foods, including any of the following:

    • Low phenylalanine content (e.g., fruit juice, fruits [except bananas], vegetables, and low-protein breads and pastas
    • Medium phenylalanine content (e.g., corn, bread, french fries, potatoes, peas, rice, and regular pasta)
    • High phenylalanine content (e.g., refried beans, chicken, nuts, hamburgers, peanuts, cheese, eggs, pork chops, steak, bananas, and milk)
  • At least 4 weeks since prior major thoracic and/or abdominal surgery and recovered
  • No prior cranial radiotherapy
  • No prior endocrine therapy, immunotherapy, or chemotherapy for the brain tumor
  • No other concurrent anticancer therapy or investigational drugs
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01233492

Locations
United Kingdom
Cancer Research UK Clinical Trials Unit - Birmingham
Birmingham, England, United Kingdom, B15 2TT
Queen Elizabeth Hospital at University Hospital of Birmingham NHS Trust
Birmingham, England, United Kingdom, B15 2TH
Sponsors and Collaborators
Cancer Research UK
Investigators
Principal Investigator: Garth Cruickshank University Hospital Birmingham
  More Information

No publications provided

Responsible Party: Cancer Research UK
ClinicalTrials.gov Identifier: NCT01233492     History of Changes
Other Study ID Numbers: CDR0000687653, CRUK-PH1/093, EUDRACT-2004-002413-37
Study First Received: November 2, 2010
Last Updated: October 7, 2013
Health Authority: United Kingdom: Medicines and Healthcare Products Regulatory Agency
United Kingdom: Research Ethics Committee

Keywords provided by Cancer Research UK:
adult glioblastoma
adult giant cell glioblastoma
adult gliosarcoma

Additional relevant MeSH terms:
Central Nervous System Neoplasms
Glioblastoma
Nervous System Neoplasms
Astrocytoma
Glioma
Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Germ Cell and Embryonal
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Neoplasms, Neuroepithelial
Nervous System Diseases
Neuroectodermal Tumors
Mannitol
Cardiovascular Agents
Diuretics
Diuretics, Osmotic
Natriuretic Agents
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses

ClinicalTrials.gov processed this record on October 23, 2014